A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Stage I Her2-positive Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have HER2-positive Stage I breast cancer. 2) Patients must have node-negative (N0) or micrometastases (N1mic) breast cancer. 3) Study requires submission of tumor blocks or slides in order to perform biomarker analyses.

You may not be eligible for this study if the following are true:

  • 1) Pregnant women. 2) Nursing women. 3) History of prior chemotherapy in the past 5 years.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.